AGLE's logo.
Ticker Symbol: AGLE

Aeglea BioTherapeutics Inc

$6.88 - 07-10-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001636282

Company Profile

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: aegleabio.com
CEO: N/A
Tags:
  • Health Technology
  • Pharmaceuticals: Major
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $13.25
Change: $1.20 ( 9.96%)
Days Range: $12.00 - $13.42
Beta: 1.10
52wk. High: $39.00
52wk. Low: $2.66
Ytd. Change 27.76%
50 Day Moving Average: $12.66
200 Day Moving Average: $9.39
Shares Outstanding: 101192921

Valuation

Market Cap: 134.1B
PE Ratio: -0.18
EPS (TTM): -71.96

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A